1. Neuroscience
Download icon

Dual leucine zipper kinase is required for mechanical allodynia and microgliosis after nerve injury

Research Article
  • Cited 5
  • Views 1,256
  • Annotations
Cite this article as: eLife 2018;7:e33910 doi: 10.7554/eLife.33910

Abstract

Neuropathic pain resulting from nerve injury can become persistent and difficult to treat but the molecular signaling responsible for its development remains poorly described. Here, we identify the neuronal stress sensor dual leucine zipper kinase (DLK; Map3k12) as a key molecule controlling the maladaptive pathways that lead to pain following injury. Genetic or pharmacological inhibition of DLK reduces mechanical hypersensitivity in a mouse model of neuropathic pain. Furthermore, DLK inhibition also prevents the spinal cord microgliosis that results from nerve injury and arises distant from the injury site. These striking phenotypes result from the control by DLK of a transcriptional program in somatosensory neurons regulating the expression of numerous genes implicated in pain pathogenesis, including the immune gene Csf1. Thus, activation of DLK is an early event, or even the master regulator, controlling a wide variety of pathways downstream of nerve injury that ultimately lead to chronic pain.

https://doi.org/10.7554/eLife.33910.001

Introduction

Neuropathic pain is a disease of the somatosensory system that is characterized by heightened sensitivity to innocuous and noxious stimuli (allodynia and hyperalgesia). This maladaptation of the pain detection system results in an important evolutionary warning signal (for example guarding a wound during tissue healing) persisting and becoming chronic and debilitating (Ji and Strichartz, 2004; Basbaum et al., 2009; von Hehn et al., 2012). Despite recent advances, the mechanisms underlying the development of neuropathic pain are still not fully understood. Characterization of signaling pathways immediately downstream of nerve injury could thus help understand the molecular and cellular changes that are critical for its development and uncover new targets for the treatment of chronic pain.

Peripheral nerve injury is a common cause of neuropathic pain in humans; the spared nerve injury (SNI) rodent model reliably replicates this type of chronic pain. In this model, partial sciatic nerve axotomy robustly results in the development of mechanical allodynia that can be measured using a reflexive behavior phenotype (paw withdrawal to a punctate touch stimulus) (Decosterd and Woolf, 2000; Bourquin et al., 2006). A correlate of the mechanical allodynia that arises following SNI is a neuroinflammatory response in the spinal cord, distant from the injury site, and characterized by an intense microgliosis in the dorsal horn of the spinal cord in the vicinity of the central nerve terminals of the injured DRG (dorsal root ganglion) neurons (Svensson et al., 1993; Ji et al., 2013). This gliosis has been the focus of many recent pain studies as the microglia are believed to contribute to an alteration in the pain transmission circuitry in the spinal cord dorsal horn (Beggs et al., 2012; Clark and Malcangio, 2014; Grace et al., 2014; Guan et al., 2016).

Dual leucine zipper kinase (DLK; Map3k12) is the critical initiator of a neuronal stress response to acute nerve injury in many neuron types across a wide range of phyla (Yan et al., 2009; Hammarlund et al., 2009; Miller et al., 2009; Watkins et al., 2013; Le Pichon et al., 2017). DLK signaling plays an important role in determining outcomes for the injured neurons including axon regeneration and neuronal survival (Yan et al., 2009; Hammarlund et al., 2009; Xiong et al., 2010; Xiong and Collins, 2012; Watkins et al., 2013) as well as axon degeneration and neuronal death (Miller et al., 2009; Ghosh et al., 2011; Watkins et al., 2013; Welsbie et al., 2013; Simon et al., 2016). However, to date, a role for DLK in the development of neuropathic pain has not been examined.

In this study, we show that genetic deletion or pharmacological inhibition of DLK greatly reduces the development of mechanical allodynia as well as the spinal cord microgliosis resulting from spared nerve injury. We find that DLK acts as a ‘master regulator’ of transcriptional changes responsible for the establishment of neuropathic pain phenotypes caused by nerve injury. These include the upregulation of immune gene Csf1 (colony stimulating factor 1) in primary sensory neurons. We thus describe for the first time the DLK-dependence of the neuronally-derived immune signal (Csf1) responsible for initiating a microglial response at a site distant from the injury (Guan et al., 2016). Our results demonstrate an essential role of DLK in the establishment of nerve injury-induced changes, including neuro-immune signaling, that result in neuropathic pain sensitization. By shedding light on the mechanisms of establishment of pain, this work can pave the way towards new treatments.

Results

DLK is required for mechanical allodynia in the SNI model of neuropathic pain

Spared nerve injury results in long lasting hypersensitivity to touch stimuli. To test whether DLK function was important in the establishment of mechanical allodynia, we conditionally deleted DLK (Map3k12) expression in adult mice by using an inducible strategy that avoids developmental effects (Map3k12fl/fl crossed to CAG-CreER+/-; [Pozniak et al., 2013]). We assessed the behavioral effect of SNI in these DLK cKO (conditional DLK knockout) versus control mice (Map3k12fl/fl; CAG-CreER-/-, referred to as DLK WT) by measuring paw withdrawal thresholds to calibrated von Frey filaments. Strikingly, DLK cKO mice were protected from developing static mechanical allodynia to punctate stimulation of their ipsilateral hind paws as compared with DLK WT littermates (Figure 1A–B). Moreover, the protection was long lasting and persisted for at least 4 weeks following injury. DLK cKO mice also showed less dynamic mechanical hypersensitivity to a light brushing stimulus (Figure 1—figure supplement 1). Importantly, deleting DLK results in no measureable behavioral deficits in the absence of injury, including normal baseline von Frey thresholds (Figure 1A), and normal motor and cognitive behaviors as shown in previous studies (Pozniak et al., 2013; Le Pichon et al., 2017). To examine how early the DLK cKO benefit was present, we tested more acute time points following SNI injury (1, 3, 5, and 7 days post injury or dpi) in a separate cohort of mice. DLK cKO mice showed less hypersensitivity as early as one dpi (Figure 1—figure supplement 2). Thus, in the absence of DLK signaling, acute and long-lasting allodynia is blocked.

Figure 1 with 3 supplements see all
DLK is necessary for the development of mechanical allodynia and induction of injury markers after spared nerve injury (SNI).

(A) DLK deletion is protective in the von Frey behavior assay following SNI at 1, 2, 3 and 4 weeks post injury (wpi). Baseline (BL) mechanical sensitivity thresholds are comparable between DLK WT (n = 9) and DLK cKO (n = 11). ****p<0.0001 by repeated measures ANOVA. (B) Scatter graph to illustrate individual points for DLK WT and DLK cKO at 4 weeks post injury. (C–H) Deletion of DLK reduces injury-induced transcription factors p-c-Jun and ATF3 in DRG following SNI. Representative images of ipsilateral L4 DRG 1 week after SNI stained for p-c-Jun in DLK WT (C) and DLK cKO (D) quantified in (E), and for ATF3 in DLK WT (F) and DLK cKO (G) quantified in (H). n = 6 per genotype. Scale bar in (G) valid for all images in this figure: 20 µm. ***p<0.001 by 2-tailed Student’s t test.

https://doi.org/10.7554/eLife.33910.002

DLK activity controls the expression of many pain-related genes

To better understand the mechanisms of these protective effects, we investigated the molecular consequences downstream of DLK signaling in peripheral sensory neurons. DLK is upstream of a kinase signaling cascade resulting in a transcriptional response to injury via phosphorylation of JNK (c-Jun N-terminal kinase) and the transcription factor c-Jun (Watkins et al., 2013; Ghosh et al., 2011; Fan et al., 1996; Cavalli et al., 2005; Fernandes et al., 2014; Larhammar et al., 2017). Given the central role of DLK in transcriptional regulation, we reasoned that this kinase might be important for regulation of multiple genes involved in neuropathic pain.

We first examined the effect of DLK deletion on the induction of transcription factors phospho-c-Jun (p-c-Jun) and ATF3 under two conditions known to cause neuropathic pain, SNI and intraplantar formalin injection. Importantly, these procedures had previously been shown to result in the upregulation of both markers (Zhuang et al., 2006; Bráz and Basbaum, 2010). Both p-c-Jun and ATF3 were induced in injured DRGs from DLK WT mice but this was prevented in DLK cKO mice under both conditions (by 65–71% with SNI, Figure 1C–H; by 90–95% in the formalin model, Figure 1—figure supplement 3). Therefore, both p-c-Jun and Atf3 can be considered downstream markers of DLK signaling in injured DRG neurons. This is consistent with previous reports of injury-induced ATF3 as downstream of DLK in another neuron type (retinal ganglion cells; (Watkins et al., 2013; Fernandes et al., 2013).

We next examined the potential DLK-dependence of changes in expression levels of genes induced following nerve injury that correlate with increased pain sensations. We therefore referred to a published transcriptomic dataset containing the list of genes whose expression is altered in the DRG following sciatic nerve transection (sample GSM1626431 from series GSE66619 [Guan et al., 2016]). Among these genes, we examined 10 among the top 25 whose expression is altered 7 days after sciatic nerve transection (Table 1). Some but not all these genes were present on a curated list of DLK-dependent genes from a microarray dataset of retinas 3 days following optic nerve crush (Watkins et al., 2013).

Table 1
Top 25 genes with altered expression 7 days following sciatic nerve transection from (Guan et al., 2016)

Genes are sorted by significance, then by fold change. The genes we examined for DLK-dependence by in situ hybridization are indicated by an asterisk *

https://doi.org/10.7554/eLife.33910.013
Genelog2 fold_change
1Sprr1a *6.96879
2Npy *5.89862
3Gpr151 *5.72999
4Cckbr *5.35581
5Ecel1 *4.97284
6Atf3 *4.95333
7Gal *4.77653
8Nts *4.60215
9Hrk4.55133
10Fst4.09785
11Lmo73.76662
12Car33.48156
13Sox11 *3.37483
14Sema6a3.32589
15Mmp163.31338
16Flrt33.28661
17Loxl23.25419
18Flnc3.21128
19Sez6l3.20287
20Adam82.98222
21Stmn42.89975
22Xdh2.77339
23Gadd45a2.66746
24Sdc12.59248
25Csf1 *2.51895

We measured mRNA expression levels at 7 dpi using quantitative in situ hybridization (RNAscope) of Atf3 as well as two neuropeptides previously documented to increase after SNI, galanin (Gal [Kashiba et al., 1992]) and neuropeptide Y (Npy [Ma and Bisby, 1998]). Strikingly, we found DLK to be responsible for injury-induced transcriptional increases of all three genes. In wild type mice, SNI upregulates Atf3, Gal and Npy, (Figure 2A,D,G). By contrast, SNI fails to upregulate these genes in DLK cKO littermates (Figure 2B–C,E–F,H–I). Other injury-induced genes that we confirmed were DLK-dependent in DRG neurons included Cckbr, Ecel1, Gpr151, Nts, Sox11, and Sprr1a (Figure 2—figure supplement 1). In all cases, the increased expression in response to injury was significantly attenuated in DLK cKO mice (Figure 2—figure supplement 1A–R).

Figure 2 with 1 supplement see all
DLK is upstream of injury-associated genesimplicated in the establishment of neuropathic pain: Atf3, Gal, Npy, and Serpina3n.

Representative images and quantification of expression of 4 genes whose expression changes following sciatic nerve axotomy: Atf3 (A–C), Gal (D–F), Npy (G–I), and Serpina3n (J–L) by in situ hybridization in DLK WT vs DLK cKO ipsilateral L3 DRG 1 week after SNI (7 dpi). Scale bar 100 µm. *p<0.05, **p<0.01, ***p<0.001 by 2-tailed Student’s t test. Averaged data for n = 4–6 sections quantified in n = 3 male mice per genotype.

https://doi.org/10.7554/eLife.33910.014

We next examined whether DLK might also be important for genes that are downregulated after injury as well. A recent study reported that SNI-induced reduction of Serine protease inhibitor 3 (Serpina3n) expression enhances mechanical allodynia (Vicuña et al., 2015). We found Serpina3n levels to be negatively regulated by DLK as evidenced by significantly higher mRNA levels after SNI in DLK cKO mice than those seen in DLK WT mice (Figure 2J–L). Therefore, the injury-induced expression changes of at least 10 genes in the DRG after SNI are DLK-dependent, suggesting that DLK is a regulator of numerous pain-associated genes.

One additional gene we focused on was colony stimulating factor 1 (Csf1), due to a recent report that this cytokine becomes neuronally expressed upon nerve injury, and is responsible for the induction of spinal cord microgliosis following nerve injury (Guan et al., 2016). The authors of this work also showed that Csf1 is required for the establishment of mechanical allodynia. We found that Csf1 induction failed to occur in DLK cKO DRG neurons examined 7 days post-SNI (Figure 3A–C), demonstrating that Csf1 upregulation depends on DLK signaling, and prompting us to examine whether microgliosis was affected in mice lacking DLK.

DLK is necessary for Csf1 upregulation in DRG neurons and for spinal cord microgliosis elicited by SNI.

(A–C) Representative images and quantification of Csf1 gene expression changes following SNI by in situ hybridization in DLK WT vs DLK cKO L3 DRG 7 days post SNI. Scale bar 100 µm. **p<0.01, by 2-tailed Student’s t test. Averaged data for n = 4–6 sections quantified in n = 3 mice per genotype. (D–I) Representative images and quantification of microgliosis in DLK WT vs DLK cKO spinal cords 8 days post-SNI. Iba1 staining in cleared spinal cords (top view, longitudinal plane) showing the SNI-induced microgliosis in the ipsilateral (left) dorsal horn of DLK WT spinal cord (D, G) that does not occur in the DLK cKO (E, H). (G) and (H) are higher magnification images of boxed areas in (D) and (E) respectively. Quantification of dorsal horn microgliosis in ipsilateral (F) and contralateral (I) spinal cord of DLK WT (n = 4) vs DLK cKO (n = 5). Scale bar in (D, E) 400 µm. Scale bar in (G, H) 100 µm. ***p=0.0010 by 2-tailed Student’s t test.

https://doi.org/10.7554/eLife.33910.018

DLK is necessary for SNI-induced spinal cord microgliosis

Microglia have been implicated as important contributors to the development of mechanical allodynia by altering the pain transmission circuitry in the spinal cord dorsal horn (Beggs et al., 2012; Clark and Malcangio, 2014; Grace et al., 2014; Guan et al., 2016). Because we had found DLK to control Csf1 expression, we examined the dorsal horn microgliosis that occurs following SNI in mice lacking DLK. Microglia in the whole lumbar spinal cord were visualized at 8 days post injury using Iba1 (ionized calcium binding adapter molecule 1) immunostaining and tissue clearing (iDisco (Renier et al., 2014); Figure 3D; see also Video 1). Strikingly, we found that microglial recruitment following SNI requires intact DLK signaling. SNI-induced ipsilateral dorsal horn microgliosis was prevented in mice lacking DLK compared to wild type controls (Figure 3D–H), while there was no difference between genotypes in the microglial density in contralateral dorsal spinal cord (Figure 3I). Therefore, DLK is essential for the spinal cord microgliosis that occurs at the central nerve terminals of DRG neurons following peripheral nerve injury, at a considerable distance from the injury site.

Video 1
untreated spinal cord, 5 dpi
https://doi.org/10.7554/eLife.33910.022

Acute time course of DLK-dependent gene expression changes and spinal cord microgliosis following sciatic nerve injury

To gain an understanding of the acute expression time course for a subset of genes transcriptionally regulated by DLK (Atf3, Csf1, Gal), we used whole sciatic nerve transection (SNT) since this injury results in the vast majority of L4 DRG neurons (87% ± 3.44 (SEM), n = 5) expressing Atf3 in the L4 DRG by 48 hr post injury. We found that injury-induced neuronal Atf3 expression plateaued early: levels were already significantly increased in ipsilateral versus contralateral L4 DRG by 18 hr (Figure 4A–B). The onset of injury-induced neuronal Csf1 expression lagged behind Atf3 with a sharp increase between 18 and 24 hr (Figure 4A,C). Ipsilateral Gal expression was significantly increased compared to contralateral by 48 hr (Figure 4D–E).

Time course of DLK-dependent gene expression in DRG neurons and corresponding spinal cord microgliosis.

(A–C) Representative images and quantification of gene expression changes in ipsilateral L4 DRGs of WT mice 6, 18, 24, 48 and 72 hr post-SNT (sciatic nerve transection). (A) and (D) Representative images of Atf3 (green), Csf1 (orange), Gal (cyan) and Tubb3 (red) in situ hybridizations in iL4 DRGs after SNT. Scale bars 100 μm. Quantification of Atf3 (B), Csf1 (C), and Gal (E) expression changes in L4 DRGs ipsilateral (green, orange, cyan iL4) vs contralateral (black, cL4) to injury 6–72 hr post-SNT. n = 4 (2 males, 2 females) for 6, 18, 24, and 48 hr groups, n = 2 (1 male, 1 female) for 72 hr group. ns: not significant; ***p<0.001, ****p<0.0001 by 2-way ANOVA followed by Sidak’s multiple comparisons post test comparing values between ipsilateral and contralateral L4 DRG at each time point. Note in (D), in representative images at 48 and 72 hr, that Gal comes on in fewer cells than for Atf3 and Csf1 (A), and these include a mixture of large and small diameter neurons. (F–G) Iba1 immunolabeling in cleared lumbar spinal cord shows no region of microglial reactivity at 18 hr post-SNI. Microgliosis becomes evident by 3 dpi and robust by 5 dpi. Representative images of 3D views from the top and the ipsilateral side (F) and quantification (G). DLK cKO prevents microgliosis in lumbar spinal cord 3 and 5 days post-SNI, as observed previously at 7 dpi (Figure 3D–H). *p<0.05, **p<0.01, ***p<0.001 by one-way ANOVA followed by Tukey’s multiple comparisons.

https://doi.org/10.7554/eLife.33910.023

We carried out a parallel spared nerve injury time course to examine the onset of spinal cord microgliosis following injury. The appearance of the microglial ‘cloud’ in the spinal cord ipsilateral to injury lags behind the increase in Csf1 expression in the DRG, in line with the report showing that Csf1 expression by injured neurons is required for the microgliosis (Guan et al., 2016). It is appreciable by 3 days, strong by 5 days post injury, but not yet apparent by 18 hr post injury (Figure 4F–G). Our time course results are consistent with previous descriptions of microgliosis resulting from traumatic nerve injury (Guan et al., 2016). The immunolabeling and clearing of whole spinal cords allows a visualization of the injury-induced microglial cloud in its entirety (see Video 1).

Treatment with DLK inhibitor GNE-3511 prevents injury-induced transcriptional changes, mechanical allodynia and microgliosis

Knowing the time course of onset of injury-induced transcriptional changes and microgliosis, we next tested whether DLK inhibition would be sufficient to prevent mechanical allodynia and microgliosis after an injury had already occurred. We dosed wild type mice twice daily with DLK inhibitor compound GNE-3511 (Patel et al., 2015) at 75 mg/kg, starting 16–18 hr post SNI (Figure 5D). This time point coincides with high Atf3 levels but precedes a sharp increase in Csf1 expression (Figure 4A,C) and the establishment of microgliosis (Figure 4F–G). Dose level and frequency were selected based on prior pharmacokinetic and pharmacodynamic studies (Patel et al., 2015; Le Pichon et al., 2017). To first verify the inhibitor compound indeed reduced DLK signaling in DRG neurons, we examined gene expression of Atf3 and Csf1 at 5 dpi in L4 DRGs in GNE-3511 versus vehicle-treated mice. GNE-3511 reversed transcriptional induction of Atf3 (which was already elevated at 18 hr, when dosing was initiated, Figure 4B) and prevented Csf1 induction (Figure 5A–C). We then proceeded to behavior testing and measurements of microgliosis in a separate group of animals. Strikingly, GNE-3511-mediated inhibition of DLK significantly prevented development of mechanical allodynia (Figure 5E), as well as the establishment of microgliosis (Figure 5F–H; Videos 12).

DLK inhibition prevents DLK-dependent gene upregulation, mechanical allodynia, and microgliosis after SNI.

(A–C) GNE-3511 treatment prevents upregulation of DLK-dependent genes in the DRG after SNI. (A) Representative images of Atf3 (green), Csf1 (orange), and Tubb3 (red) in situ hybridizations in ipsilateral L4 DRGs from vehicle-treated, GNE3511-treated, and DLK cKO mice 5 days post-SNI. Scale bar 100 μm. (B, C) Quantification of neuronal gene expression intensity in ipsilateral L4 DRGs at 5 dpi showing reduced expression of Atf3 (B) and Csf1 (C) in DLK cKO and GNE-3511 vs vehicle treated mice (n = 2 per group). *p<0.05, **p<0.01 by Tukey’s multiple comparisons test. (D) DLK inhibitor study design. vF: von Frey; BL: baseline; SNI: spared nerve injury; 1 w: 1 week post SNI; TH: tissue harvest. Twice daily dosing of GNE-3511 began at 18 hr post injury (hpi). (E) DLK inhibitor GNE-3511 prevents mechanical allodynia measured 1 week post injury. Vehicle n = 12; GNE-3511 n = 17. ***p=0.0004 for genotype by 2-way ANOVA. (F–H) GNE-3511 prevents the spinal cord microgliosis elicited by SNI as shown by Iba1 staining in cleared immunostained lumbar spinal cord. Representative images from vehicle (F) vs GNE-3511 treated mice (G) and quantification of Iba1-positive signal in ipsilateral spinal cord (H). Vehicle n = 4; GNE-3511 n = 7. ***p=0.0001 by 2-tailed Student’s t test. Scale bar in (F), (G) 400 µm.

https://doi.org/10.7554/eLife.33910.026
Video 2
GNE-3511-treated spinal cord, 5 dpi
https://doi.org/10.7554/eLife.33910.030

Discussion

Our results thus reveal DLK signaling to be a critical step in the molecular pathway that results in the establishment of neuropathic pain following peripheral nerve injury. Both the genetic and pharmacological methods of DLK inhibition demonstrate that the transcriptional response downstream of DLK causes the spinal cord microgliosis as well as heightened withdrawal responses to touch stimuli.

Our findings provide a mechanistic explanation of how DLK deletion blocks the development of mechanical allodynia after SNI (Figure 6). Although our Cre driver line results in global DLK deletion, in this work we focused on the effect of DLK loss in peripheral neurons, and found many cell-autonomous gene expression changes in the injured DRGs that are DLK-dependent. It will be of great interest to delete DLK specifically in sensory neurons to assess whether this recapitulates the effect of global DLK deletion or whether DLK activity in other cell types is also important to produce the mechanical allodynia we have described.

Schematic of DLK activation in DRG neurons following spared nerve injury.

Nerve injury activates DLK (Ji and Strichartz, 2004) which induces a transcriptional response in DRG neurons (Basbaum et al., 2009), including Csf1 upregulation (von Hehn et al., 2012) which leads to microgliosis in the spinal cord (Decosterd and Woolf, 2000). Overall, the transcriptional changes induced by DLK lead to the establishment of touch-evoked pain (Bourquin et al., 2006) as evidenced by the paw withdrawal reflex (Svensson et al., 1993).

https://doi.org/10.7554/eLife.33910.031

It is particularly notable that DLK activity is essential for Csf1 upregulation in sensory neurons. In light of recent work showing that neuronal expression of Csf1 is necessary and sufficient for the establishment of mechanical allodynia via recruitment of microglia to the dorsal horn (Guan et al., 2016), we now provide an explanation for how nerve injury upregulates Csf1 expression. Our work places DLK upstream of neuronal Csf1 expression, revealing a mechanism whereby an immune response can be elicited by injured neurons in the form of microglial recruitment at a site distant from the injury. The significance of this finding extends beyond the case of traumatic nerve injury to other contexts of neuronal injury and dysfunction, for example neurodegenerative disease, in which gliosis is a frequent correlate of neuronal pathology and neuroinflammation is known to play an important role (Ransohoff, 2016; Salter and Stevens, 2017). In fact, our previous work found that deleting DLK in a mouse model of neurodegenerative disease also reduced microgliosis (Le Pichon et al., 2017), and another study had also found that DLK deletion prevented microgliosis resulting from facial motor neuron injury (Itoh et al., 2014). Interestingly, a recent report found that a related injury signaling pathway, Sarm1, also controls a neuro-immune response (Wang et al., 2018). The authors reported that Sarm1 is responsible for upregulating several chemokine ligand genes via JNK and c-Jun, but not Csf1, whose upregulation is however c-Jun-dependent.

Neuropathic pain is poorly treated by current pain therapies; thus, finding effective drugs to prevent or treat this debilitating chronic syndrome is of critical importance especially in light of the current opioid epidemic (Wilkerson et al., 2016). Our identification of DLK as an upstream regulator of pathways that result in chronic pain provides a new logic for designing and testing therapeutic strategies.

Materials and methods

Key resources table
Reagent type
(species) or resource
DesignationSource or referenceIdentifiersAdditional information
Commercial
assay/kit- RNAscope
RNAscope Fluorescent
Multiplex Detection
Reagents
Advanced
Cell Diagnostics
ACD:320851
Commercial
assay/kit- RNAscope
RNAscope
Probe-Mm-Atf3; Atf3
Advanced
Cell Diagnostics
ACD:426891
Commercial
assay/kit- RNAscope
RNAscope
Probe-Mm-Serpina3n;
Serpina3n
Advanced
Cell Diagnostics
ACD:430191
Commercial
assay/kit- RNAscope
RNAscope
Probe-Mm-Csf1; Csf1
Advanced
Cell Diagnostics
ACD:315621
Commercial
assay/kit- RNAscope
RNAscope
Probe-Mm-Tubb3;
Tubb3
Advanced
Cell Diagnostics
ACD:423391
Commercial
assay/kit- RNAscope
RNAscope
Probe-Mm-Gal;
Galanin; Gal
Advanced
Cell Diagnostics
ACD:400961
Commercial
Assay/kit- RNAscope
RNAscope
Probe-Mm-Npy; Npy
Advanced
Cell Diagnostics
ACD:313321
Commercial
assay/kit- RNAscope
RNAscope
Probe-Mm-Cckbr; Cckbr
Advanced
Cell Diagnostics
ACD:439121
Commercial
assay/kit- RNAscope
RNAscope
Probe-Mm-Ecel1; Ecel1
Advanced
Cell Diagnostics
ACD:475331
Commercial
assay/kit- RNAscope
RNAscope
Probe-Mm-Gpr151; Gpr151
Advanced
Cell Diagnostics
ACD:317321
Commercial
assay/kit- RNAscope
RNAscope
Probe-Mm-Nts; Nts
Advanced
Cell Diagnostics
ACD:420441
Commercial
assay/kit- RNAscope
RNAscope
Probe-Mm-Sox11; Sox11
Advanced
Cell Diagnostics
ACD:440811
Commercial
assay/kit- RNAscope
RNAscope
Probe-Mm-Sprr1a; Sprr1a
Advanced
Cell Diagnostics
ACD:426871
Antibodyanti-phospho-c-Jun
S63 (rabbit polyclonal)
Cell SignalingCell Signaling:9261;
RRID:AB_2130162
1:500
Antibodyanti-NeuN
(mouse monoclonal)
MilliporeMillipore:MAB377;
RRID:AB_2298772
1:300
Antibodyanti-ATF3
(rabbit polyclonal)
Santa CruzSanta Cruz:sc-188;
RRID:AB_2258513
1:3000
Antibodyanti-Iba1
(rabbit polyclonal)
WakoWako:019–19741;
RRID:AB_2665520
1:200; 1:600
AntibodyDonkey anti-rabbit
AlexaFluor 647
ThermoFisherThermoFisher:A31573;
RRID:AB_2536183
1:500 for immunostaining;
1:600 for iDisco
AntibodyDonkey anti-rabbit
AlexaFluor 594
ThermoFisherThermoFisher:A21207;
RRID:AB_141637
1:500 for immunostaining;
1:600 for iDisco
AntibodyDonkey anti-mouse
AlexaFluor 488
ThermoFisherThermoFisher:A21202;
RRID:AB_141607
1:500 for immunostaining;
1:600 for iDisco
Strain, strain
background
(mus musculus)
Inbred strain C57BL/6J
(mus musculus)
The Jackson LaboratoryJax:000664;
RRID:IMSR_JAX:000664
Strain, strain
background
(mus musculus)
STOCK Tg(CAG-cre/Esr1*)
5Amc/J, C57BL/6J
(mus musculus)
The Jackson LaboratoryJax:004453;
RRID:IMSR_JAX:004453
Strain, strain
background
(mus musculus)
Map3k12 flox mouse,
C57BL/6J (mus musculus)
Genentech, by MTA;
PMID 24166713
Chemical compound,
drug
small molecule
GNE-3511 (DLK inhibitor)
Genentech, by MTA;
PMID 25341110
Software, algorithmFIJINIHRRID:SCR_002285
Software, algorithmarivis Vision 4DArivis

Mice

All animal care and experimental procedures were performed in accordance with protocols approved by the National Institutes of Neurological Diseases and Stroke and the National Institute of Child Health and Human Development Animal Care and Use Committees. Map3k12fl/fl mice (Le Pichon et al., 2017; Pozniak et al., 2013) were bred to a CAG-CreER transgenic line (Jax#004453). Map3k12fl/fl; CAG-CreER-/- mice were referred to as DLK WT; Map3k12fl/fl. CAG-CreER+/- mice were referred to as DLK cKO. C57BL/6J mice (Jax#000664) were used in the DLK inhibitor study. Similar numbers of male and female mice were used in all experiments except where stated.

Tamoxifen administration

Map3k12fl/fl; CAG-CreER mice were placed on a diet containing 40 mg/kg Tamoxifen (Envigo TD.130860) for 3 weeks, and back onto regular chow for at least 3 weeks prior to any further testing or tissue harvest. Mice in Figure 1—figure supplement 1 and 2, received five consecutive daily doses of 200 mg/kg tamoxifen in corn oil by oral gavage, and received no further treatment for 1 week before receiving SNI. All mice, including Cre negative (CreER-/-) mice, were Tamoxifen-treated.

Nerve injury models

For intraplantar formalin injections, a 10 µl volume of 5% formalin in PBS was injected into one hindpaw of mice under isoflurane anesthesia. n = 2 male DLK WT, 2 male and one female DLK cKO. For spared nerve injury surgery (SNI), the sural and superficial peroneal branches of the sciatic nerve were ligated (size 8.0 suture thread) and transected, leaving the tibial nerve intact. The muscle tissue overlying the injury was gently placed back together and the skin held together with wound clips which were removed 5 days later. In Figure 1, n = 9,DLK WT (4 males and 5 females) and 11 DLK cKO (6 males and 5 females). For sciatic nerve transection, the entire sciatic nerve was transected at the mid-thigh level. The overlying muscle was placed back together and the skin was held together with wound clips. For experiments in Figures 13, 5D-H, no post-operative analgesia was provided. For experiments in Figures 4, 5A–C, and in Figure 1—figure supplement 1, the following analgesia was provided on the day of surgery and for the next 2 days: buprenorphine (0.05 mg/kg) once daily IP for 3 days, and ketoprofen (5 mg/kg) once daily subcutaneously for 3 days.

Von Frey behavior test (static allodynia)

Behavioral experiments were done blind to genotype or treatment. Mice were habituated for 15–30 min to inverted glass staining jars (10 cm long x 8.5 cm wide x 7 cm tall) placed on a wire mesh platform. White paper was placed between each chamber so the mice could not see each other. Only mice of the same sex were tested in the same session. Von Frey filaments were manually applied to the center of the mouse’s ipsilateral hind paw (territory innervated by the tibial nerve). The following filaments were tested: 0.008, 0.02, 0.04, 0.07, 0.16, 0.4, 0.6, 1, 1.4 g. Testing was performed essentially as described in (Latremoliere et al., 2015). Each animal received 10 stimulations with each filament. The inter trial interval was at least 15 s. If a mouse showed paw withdrawal responses or escape attempts for five trials or more out of 10, that filament force was considered its mechanical threshold. Testing began using the 0.04 g filament. If a mouse responded to a given filament, the following stimulus used the next lowest filament. If a mouse failed to show a withdrawal response, the following stimulus used the next highest filament. Once a mouse responded all 10 times to a given filament, no further testing of higher force filaments was performed, but they were scored as a 10/10 for graphing and analysis purposes.

Light brushing behavior test (dynamic allodynia)

Mice were lightly stroked on the base of their injured paw from their heel towards the center of their paw pad with a trimmed paintbrush (5/0) and at a velocity of ~2 cm/s as described in (Cheng et al., 2017). Scoring system: 0 – rapid paw lift (typical response of an uninjured mouse; lasts <1 s); 1 – sustained paw lift into the body (>2 s); 2 – lateral kick or startle-like jump; 3 – paw licking (or tending to paw with mouth) or multiple flinching responses. Each trial consisted of up to five brush strokes, where if the mouse responded with a score greater than 0, the trial was terminated with that score. The inter-trial interval was at least 3 min. Each mouse was given four trials and the average score was calculated.

GNE-3511 dosing

GNE-3511 was synthesized as described in (Patel et al., 2015) and formulated in a solution of 0.5% w/v USP Grade Methyl Cellulose and 0.2% v/v Tween 80 in water. The solution was sonicated and stored at 4°C for no more than 7 days. Mice were dosed twice daily (BID) at 75 mg/kg with a 10 ml/kg of a 7.5 mg/ml solution of GNE-3511 or vehicle alone by oral gavage. The last dose was administered 2 hr prior to tissue harvest.

Tissue harvest and preparation

Mice were anesthetized with isoflurane, decapitated. L3 and L4 DRGs were harvested from the contralateral and ipsilateral sides to the injury, and snap frozen on dry ice. The DRGs were embedded in OCT and sectioned at 10–20 µm for staining or in situ hybridization. For spinal cord harvest, mice were transcardially perfused with PBS and decapitated. A cut was made through the spinal column at the level of the hip bones (sacral) and a PBS-filled syringe fitted with a 20G needle (7.25 mm) was inserted into the caudal end of the spinal column to flush the spinal cord out. Spinal cords were then fixed in 4% paraformaldehyde overnight at 4°C.

Immunostaining

Fresh frozen sections were briefly fixed in 4% paraformaldehyde in phosphate buffered saline (PBS) for 15 min on ice, then washed in PBS followed by PBS containing 0.1% Triton X (PBSTx). Sections were blocked in 5% normal donkey serum in PBS for 1–2 hr at room temperature and incubated with primary antibody diluted in 0.5% normal donkey serum in PBS overnight at 4°C. Slides were washed in PBSTx, then incubated in AlexaFluor-conjugated secondary antibodies (ThermoFisher) in PBS for 2 hr at room temperature, followed by two washes in PBSTx and two in PBS. Slides were coverslipped using Prolong Gold Antifade Mountant containing DAPI (4’,6-diamidino-2-phenylindole) nuclear counterstain (ThermoFisher #P-36931).

Antibodies

Primary antibodies: rabbit anti-ATF3 (Santa Cruz #sc-188, 1:3000), rabbit anti-phospho-c-Jun (Cell Signaling #9261, 1:500), mouse anti-NeuN (Millipore #MAB377, 1:300).

Secondary antibodies: donkey anti-mouse and donkey anti-rabbit AlexaFluor conjugates (ThermoFisher; 1:500).

RNAscope in situ hybridization

 Multiplex in situ hybridization was performed according to the manufacturer’s instructions (Advanced Cell Diagnostics #320850). Briefly, 10–16 µm-thick fresh frozen sections were fixed in 4% paraformaldehyde, treated with Proteinase K , and hybridized with gene-specific probes to mouse Atf3, Cckbr, Csf1, Ecel1, Gal, Gpr151, Npy, Nts, Serpina3n, Sox11, and Sprr1a. In situ experiments shown in Figures 2 and 3 were from L3 (lumbar level 3) DRGs. All other in situ data used lumbar 4 (L4) DRGs.

iDisco procedure and imaging

The iDisco protocol was followed as described in (Renier et al., 2014) and https://idisco.info. Rabbit anti-Iba1 (Wako #019–19741) was used at 1:100 in Figure 3 at 1:200 in Figure 5 during a 3 day incubation at 37°C. Secondary antibody AlexaFluor594-conjugated donkey anti-rabbit (ThermoFisher #A21207) was used at 1:200 in Figure 3, and an AlexaFluor647-conjugate at 1:600 in Figure 5. Spinal cords were embedded in 1% agarose prior to clearing to facilitate handling for imaging. Imaging of iDisco samples was done using a two-photon microscope (Olympus MPE-RS; representative images in Figures 3 and 5) as well as a light sheet microscope (LaVision Biotec Ultramicroscope II; quantification of all spinal cord samples in Figures 3 and 5, and videos). Imaging on the LaVision Biotec UltraMicroscope II was performed using their 4x objective. All images were acquired using six light-sheets with dynamic focusing (16 positions) enabled. For the Dynamic Focus Processing and Merge Lightsheet calculations, the Contrast Adaptive and Contrast algorithms were respectively used.

Imaging and analysis of immunostaining and in situ hybridization in Figures 13

Sections were imaged by confocal microscopy (Olympus FV1000; Zeiss LSM780) and analyzed using FIJI software (National Institutes of Health) by an experimenter blind to genotype or treatment. For immunostaining in DRG, ATF3, p-c-Jun, and NeuN positive-stained cells were counted manually in 3 images per animal. For gene expression by in situ hybridization in DRG in Figures 2, 3, 4-6 DRG sections from each animal were analyzed and averaged, with n = 3 male mice per genotype. ROIs were drawn around the areas of DRG containing cell bodies, excluding areas containing only nerve. Images were thresholded into a binary signal and the percent area of fluorescent signal was quantified.

Imaging and analysis of gene expression by in situ hybridization in Figures 45

Confocal stacks were acquired on a Zeiss LSM780 or 800 using a 20X objective. Laser power, gain, and digital offset were kept constant for all channels other than DAPI. Tile region and z-stack range varied for individual DRGs, with a range of 8–20 z-stacks depending on tissue organization. RNA expression intensities were obtained and quantified using an in-house built segmentation pipeline in Arivis Vision4D. For all images, the range of the Tubb3-positive region over multiple z-stacks was used to define the working volume. This region was isolated from surrounding nerve tissue using a denoising filter followed by a blob finder. A curvature flow filter with 20 iterations and a working time of 0.1 was used to denoise the Tubb3 signal. Next a blob finder with a diameter of 50 µm, threshold of 1.00 and split sensitivity of 96 was applied to the denoised image stack in order to define the Tubb3 region into multiple small volumes. (Images taken on the ZEISS MIC800 used a blob finder with a diameter of 40 µm, threshold of 1.00 and split sensitivity of 93.4 to achieve similar results). Blob finder volumes that did not correspond with DAPI positive regions of tissue were deleted manually. Remaining volumes were then summed to produce a total Tubb3-positive volume specific to each DRG. RNA probe intensities within these Tubb3 regions were summed to give the total RNA intensity per Tubb3 volume for each individual DRG.

Analysis of Iba1 signal in spinal cord

For Iba1 signal shown in Figures 3 and 5, 4–6 images from Z planes regularly spaced within the entire dorsal horn region of the spinal cord were analyzed and averaged per animal. ROIs were manually drawn, images thresholded, and the percent area of Iba1-positive signal quantified. For quantification of Iba1-positive volumes or ‘clouds’ in Figure 4, the following method was employed. Tiff images acquired on the Ultramicroscope II were converted into .SIS files. In arivis Vision4D (2.12.6), an in-house developed analysis pipeline was run on each sample. The pipeline created a 3D annotation to capture the size and intensity of regions containing many Iba1+ cells. This was done by the use of a rigorous De-Noising Mean Filter with a voxel radius of 10, after which a 3D Intensity Threshold was applied, and to which a Segment Filter of 0.001 mm3 was used to filter out very small annotations.

Videos

Image stacks taken with the Ultramicroscope II were converted to 3D video files using arivis software (Vision 4D).

Statistical analysis

All data were analyzed using Graphpad Prism software. Specific tests employed are described in each figure legend.

References

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41

Decision letter

  1. David D Ginty
    Reviewing Editor; Harvard Medical School, United States

In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.

Thank you for submitting your article "Dual Leucine Zipper Kinase is required for mechanical allodynia and microgliosis after nerve injury" for consideration by eLife. Your article has been favorably evaluated by a Senior Editor and two reviewers, one of whom is a member of our Board of Reviewing Editors. Your article has been reviewed by 2 peer reviewers, and the evaluation has been overseen by a Reviewing Editor and a Senior Editor. The reviewers have opted to remain anonymous.

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

Summary:

The manuscript by Le Pichon et al. demonstrates an important role for the dual leucine zipper kinase (DLK) in static mechanical allodynia. Authors demonstrate that mice with a deletion of the kinase in the adult show significantly reduced static allodynia with no effect on baseline von Frey threshold. Systemic delivery of an inhibitor of DLK twice per day for a week also reduced the allodynia measured at one week. The authors also show that microglia in the dorsal horn (detected with Iba1 staining) after SNI are reduced in the absence of DLK or with the inhibitor. Next the authors demonstrate (in the supplementary) that induction of ATF3 and p-c-Jun by SNI or formalin injection are reduced in DLK cKO or with the inhibitor. Based on this, they look at the change in mRNA levels for genes thought to be downstream of these proteins (Gal, NPY, Csf1, Serpina3n) in the cKO after SNI, demonstrating changes consistent with their proposed roles at least for the last two genes. Finally, the authors use a database of genes that were shown to be upregulated by SNI, they pick 7 of these and then show that they are not upregulated in the cKO after SNI (also in supplementary).

The paper is following on the heels of work by this author and others that DLK has a role in the stress response to nerve damage and that inhibiting it can be beneficial after the insult. In earlier work, Pichon and previous colleagues performed a transcriptome study of the genes that are up and down regulated 3 days after optic nerve crush in inhibitor and vehicle treated animals. Induction of ATF3 was identified as being suppressed by the inhibitor. A decrease in the amount of p-c-Jun was also demonstrated in this study.

The data are solid and the authors do a nice job of suggesting a potential link between DNK and the regulation of genes previously shown to be important for nerve injury induced mechanical allodynia induced with Csf1 and Serpina3n being the main ones.

Essential revisions:

1) Although the simplest interpretation of the authors' findings is that DLK is required cell-autonomously in DRG sensory neurons, it is possible that the DLK gene is required in some cell type other than primary sensory neurons because the CreER line used (ROSA-CAG-CreERT2) is ubiquitously expressed. This issue needs to be addressed with experiments, if possible, or if not then it should be discussed in detail.

2) What is the earliest time-point that one can observe punctate allodynia after SNI? Also, what is the rationale for delivering the inhibitor for a week before testing the allodynia? Some discussion of this should be made. Allodynia measured at 16 hours, and daily for a week would be better.

3) A strength of the study is the potential for translating the findings for treatment of chronic pain after nerve injury. The reviewers would like to see additional experiments that ask how long after SNI surgery can the drug be applied and still show an effect? A later time point after injury (e.g. 3-7 days) to test whether it still has an effect would be particularly informative since most patients seek relief later and this drug has been implicated in reversing degeneration and nerve damage.

4) What is the evidence for efficacy and specificity of GNE-3511 towards DLK in DRG neurons in vivo? If there is a measure of DLK activity, does GNE-3511 lead to inhibition of this activity in DRG neurons at doses that correspond to those needed for inhibition of mechanical allodynia and gliosis?

https://doi.org/10.7554/eLife.33910.036

Author response

Essential revisions:

1) Although the simplest interpretation of the authors' findings is that DLK is required cell-autonomously in DRG sensory neurons, it is possible that the DLK gene is required in some cell type other than primary sensory neurons because the CreER line used (ROSA-CAG-CreERT2) is ubiquitously expressed. This issue needs to be addressed with experiments, if possible, or if not then it should be discussed in detail.

As requested we now include a detailed discussion on this point in the manuscript (Discussion, second paragraph).

We agree it would have been ideal to generate a mouse with sensory neuron-specific deletion of DLK, but the timeline to generate such mice was impractical.

2) What is the earliest time-point that one can observe punctate allodynia after SNI? Some discussion of this should be made. Allodynia measured at 16 hours, and daily for a week would be better.

We have addressed this point in a new experiment to see how early punctate allodynia can be observed. We tested DLKWT vs. DLKcKO mice at 1, 3, 5 and 7 days post injury (dpi) (Figure 1—figure supplement 2). At 1 dpi, control mice (but not the knockouts) displayed mechanical allodynia; however, sensitization was far lower at 3 and 5 days post-SNI. We have concerns that the mice are still recovering from surgery e.g. damage to muscle and skin (and presence of wound clips) as well as nerve injury during this first week. Reliable allodynia is observed in the control group at 7 dpi. See text in Figure 1—figure supplement 2 legend.

Notably, we also measured the time-course for transcriptional changes and microgliosis and we show that these occur over the first week after nerve injury in parallel with the development of static mechanical allodynia. These new data are shown in Figure 4.

Also, what is the rationale for delivering the inhibitor for a week before testing the allodynia?

We now discuss the rationale for the inhibitor experiment design in the subsection “Treatment with DLK inhibitor GNE-3511 prevents injury-induced transcriptional changes, mechanical allodynia and microgliosis”, based on results shown in Figure 4.

3) A strength of the study is the potential for translating the findings for treatment of chronic pain after nerve injury. The reviewers would like to see additional experiments that ask how long after SNI surgery can the drug be applied and still show an effect? A later time point after injury (e.g. 3-7 days) to test whether it still has an effect would be particularly informative since most patients seek relief later and this drug has been implicated in reversing degeneration and nerve damage.

The focus of our study is the role for DLK in establishing pain sensitivity. We agree it would be interesting to test the effect of starting DLK inhibitor treatment at different time points after injury. But because of the competing effects of SNI and blocking DLK this would really require a comprehensive evaluation (rather than a single time point) and is beyond the scope of the present study. Importantly, our new data do demonstrate that blocking DLK reverses Atf3 induction: compare normal Atf3 induction at 18h (Figure 4) with 5 dpi (Figure 5); discussed in the subsection “Treatment with DLK inhibitor GNE-3511 prevents injury-induced transcriptional changes, mechanical allodynia and microgliosis”.

4) What is the evidence for efficacy and specificity of GNE-3511 towards DLK in DRG neurons in vivo? If there is a measure of DLK activity, does GNE-3511 lead to inhibition of this activity in DRG neurons at doses that correspond to those needed for inhibition of mechanical allodynia and gliosis?

We have previously generated data on the pharmacokinetic and pharmacodynamic properties of GNE-3511 towards DLK, as well as its efficacy and specificity (Patel et al., 2015, Le Pichon et al., 2017). This guided our selection of the dose level and dosing frequency. In our published work, we have shown that GNE-3511 has the expected pharmacodynamic effect for DLK inhibition in vivo by reducing phospho-c-Jun in retinal ganglion cells and motor neurons. Here, in our revision, we have extended this to DRG neurons as we show in Figure 5A-C the efficacy of GNE-3511 treatment on downstream transcriptional targets of DLK. GNE-3511 prevents the upregulation of Atf3 and Csf1 in DRG neurons at 5 days post SNI, just as we saw in the DLK cKO (shown in Figure 2).

https://doi.org/10.7554/eLife.33910.037

Article and author information

Author details

  1. Josette J Wlaschin

    Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, United States
    Contribution
    Data curation, Formal analysis, Investigation, Visualization, Methodology, Writing—review and editing
    Contributed equally with
    Jacob M Gluski and Eileen Nguyen
    Competing interests
    No competing interests declared
  2. Jacob M Gluski

    Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, United States
    Contribution
    Data curation, Formal analysis, Investigation, Visualization, Methodology, Writing—review and editing
    Contributed equally with
    Josette J Wlaschin and Eileen Nguyen
    Competing interests
    No competing interests declared
  3. Eileen Nguyen

    National Center for Complementary and Integrative Health, National Institutes of Health, Bethesda, United States
    Contribution
    Data curation, Formal analysis, Investigation, Methodology
    Contributed equally with
    Josette J Wlaschin and Jacob M Gluski
    Competing interests
    No competing interests declared
  4. Hanna Silberberg

    Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, United States
    Contribution
    Data curation, Formal analysis, Investigation, Methodology, Writing—review and editing
    Competing interests
    No competing interests declared
  5. James H Thompson

    National Center for Complementary and Integrative Health, National Institutes of Health, Bethesda, United States
    Contribution
    Investigation
    Competing interests
    No competing interests declared
  6. Alexander T Chesler

    National Center for Complementary and Integrative Health, National Institutes of Health, Bethesda, United States
    Contribution
    Conceptualization, Resources, Data curation, Formal analysis, Supervision, Funding acquisition, Investigation, Visualization, Methodology, Writing—original draft, Project administration, Writing—review and editing
    For correspondence
    alexander.chesler@nih.gov
    Competing interests
    No competing interests declared
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-3131-0728
  7. Claire E Le Pichon

    Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, United States
    Contribution
    Conceptualization, Resources, Data curation, Formal analysis, Supervision, Funding acquisition, Investigation, Visualization, Methodology, Writing—original draft, Project administration, Writing—review and editing
    For correspondence
    claire.lepichon@nih.gov
    Competing interests
    No competing interests declared
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-9274-3615

Funding

National Center for Complementary and Integrative Health (Intramural Research Program)

  • Alexander T Chesler

National Institutes of Health (Intramural Research Program - DDIR Innovation Award)

  • Alexander T Chesler
  • Claire E Le Pichon

National Institute of Child Heath and Human Development (Intramural Research Program)

  • Claire E Le Pichon

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Acknowledgements

DLKlox/lox; CAG-CreERT2 mice and DLK inhibitor GNE-3511 were obtained from Genentech by MTA. We would like to thank the NINDS animal care technicians and veterinary staff for assistance with mouse care, as well as Nick Ryba, Mark Hoon, Joseph Lewcock, and Morgan Sheng for helpful discussions and comments on the manuscript. This work was funded by the Intramural Program at National Institutes of Health (IRP-NIH) through NCCIH (ATC) and NICHD (CELP). Further support was provided by the NIH DDIR Innovation Award (CELP and ATC).

Ethics

Animal experimentation: All animal care and experimental procedures were performed in accordance with protocols approved by the National Institutes of Neurological Diseases and Stroke Animal Care and Use Committee (protocols #1365-14, 1369-14, and 1365-17) and by the National Institute of Child Health and Human Development Animal Care and Use Committee (protocol #17-003).

Reviewing Editor

  1. David D Ginty, Harvard Medical School, United States

Publication history

  1. Received: November 28, 2017
  2. Accepted: June 10, 2018
  3. Version of Record published: July 3, 2018 (version 1)

Copyright

This is an open-access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the Creative Commons CC0 public domain dedication.

Metrics

  • 1,256
    Page views
  • 191
    Downloads
  • 5
    Citations

Article citation count generated by polling the highest count across the following sources: Scopus, Crossref, PubMed Central.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Download citations (links to download the citations from this article in formats compatible with various reference manager tools)

Open citations (links to open the citations from this article in various online reference manager services)